VCEL Stock Summary and Trading Ideas (Vericel | NASDAQ:VCEL)

Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Vericel trades on the NASDAQ stock market under the symbol VCEL.

As of November 10, 2026, VCEL stock price climbed to $58.91 with 799,883 million shares trading.

VCEL has a beta of -0.12, meaning it tends to be less sensitive to market movements. VCEL has a correlation of 0.00 to the broad based SPY ETF.

VCEL has a market cap of $3.02 billion. This is considered a Mid Cap stock.

Last quarter Vericel reported $85 million in Revenue and $.27 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.22.

In the last 3 years, VCEL traded as high as $63.00 and as low as $28.95.

The top ETF exchange traded funds that VCEL belongs to (by Net Assets): IJR, IWM, XBI, VTI, IWO.

VCEL has outperformed the market in the last year with a price return of +51.3% while the SPY ETF gained +12.8%. VCEL has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +30.6% and +36.9%, respectively, while the SPY returned -2.8% and -2.1%, respectively.

VCEL support price is $56.71 and resistance is $60.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VCEL shares will trade within this expected range on the day.